PHILADELPHIA, PA, August 20, 2024 — IntegriChain, the leading provider of revenue optimization technology and insights for the pharmaceutical industry, today announced the appointment of Matt Heyman as Chief Financial Officer. Heyman brings to IntegriChain more than a decade of experience in corporate finance, strategy, and M&A, predominately within public and private software businesses.

“IntegriChain is poised for significant growth in the coming years as we focus on our mission – to help pharma innovators develop, implement, and operate sustainable growth strategies for life-changing science,” said Josh Halpern, Co-Founder and CEO of IntegriChain. “We are thrilled to have Matt join us with his depth of experience in corporate finance and development, growing SaaS companies, and partnering with strategic investors.”

“I am excited to join the IntegriChain leadership team at this pivotal moment,” said Heyman. “The company has developed into a leading platform that uniquely combines data, technology, outsourcing, and consulting to address the essential challenges of drug commercialization in today’s market. I look forward to helping IntegriChain execute its vision organically and inorganically as we continue to build out the ICyte Platform and arm our pharma customers with the keys they need to deliver renewed growth.”

About Matt Heyman

Heyman will be responsible for IntegriChain’s Global Finance and Accounting operations. He previously held numerous leadership roles at Diligent Corporation over the last eight years, most recently as the Senior Vice President, Finance and Corporate Development. During his tenure at Diligent, revenue increased fivefold, and he led numerous strategic acquisitions. Prior to Diligent, Heyman served on the corporate development team at the SaaS business Fleetmatics (NYSE:FLTX) through a successful acquisition by Verizon. He began his career in the investment banking and management consulting industries. Heyman earned a BA degree in economics from The George Washington University.

About IntegriChain

IntegriChain delivers biopharma’s only comprehensive data-driven commercialization platform from strategy to operational execution, connecting the commercial, financial, and operational dimensions of drug access and profitability. Our ICyte® Platform integrates technology, data, consulting, and managed services to unify critical workflows, replacing manual processes with integrated analytics and precision controls.

Biopharma relies on IntegriChain to optimize patient access and net revenue performance, reduce leakage, and strengthen compliance, ensuring every life-changing therapy reaches patients with speed, affordability, and sustainability. Backed by Nordic Capital, a leading sector-specialized private equity investor with a broad portfolio in healthcare and technology.

IntegriChain is headquartered in Philadelphia, PA, with a location in Pune, India.

Media Contact

Jennifer Guinan, Sage Strategic Marketing

jennifer@sagestrat.com